Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach

Manuel Salto-Tellez; Ming-Sound Tsao; Jin-Yuan Shih; Sumitra Thongprasert; Shun Lu; Gee-Chen Chang; Joseph Siu-Kie Au; Teh-Ying Chou; Jong-Seok Lee; Yuan-Kai Shi; Ahmad Radzi; Jin-Hyoung Kang; Sang-We Kim; Soo-Yong Tan; James Chih-Hsin Yang

doi:10.1097/JTO.0b013e318227816a

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach

Manuel Salto-Tellez, Ming-Sound Tsao, Jin-Yuan Shih, Sumitra Thongprasert, Shun Lu, Gee-Chen Chang, Joseph Siu-Kie Au, Teh-Ying Chou, Jong-Seok Lee, Yuan-Kai Shi, Ahmad Radzi, Jin-Hyoung Kang, Sang-We Kim, Soo-Yong Tan, James Chih-Hsin Yang

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols.

Original language	English
Pages (from-to)	1663-9
Number of pages	7
Journal	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Volume	6
Issue number	10
DOIs	https://doi.org/10.1097/JTO.0b013e318227816a
Publication status	Published - Oct 2011

Keywords

Far East
Neoplasm Staging
Receptor, Epidermal Growth Factor
Antineoplastic Agents
Pathology, Molecular
DNA Mutational Analysis
Humans
Drug Resistance, Neoplasm
Asian Continental Ancestry Group
Individualized Medicine
Survival Rate
Lung Neoplasms
Treatment Outcome
Practice Guidelines as Topic
Carcinoma, Non-Small-Cell Lung
Mutation

Access to Document

10.1097/JTO.0b013e318227816a

Fingerprint Dive into the research topics of 'Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach'. Together they form a unique fingerprint.

Cite this

Salto-Tellez, M., Tsao, M-S., Shih, J-Y., Thongprasert, S., Lu, S., Chang, G-C., Au, J. S-K., Chou, T-Y., Lee, J-S., Shi, Y-K., Radzi, A., Kang, J-H., Kim, S-W., Tan, S-Y., & Yang, J. C-H. (2011). Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 6(10), 1663-9. https://doi.org/10.1097/JTO.0b013e318227816a

Salto-Tellez, Manuel ; Tsao, Ming-Sound ; Shih, Jin-Yuan ; Thongprasert, Sumitra ; Lu, Shun ; Chang, Gee-Chen ; Au, Joseph Siu-Kie ; Chou, Teh-Ying ; Lee, Jong-Seok ; Shi, Yuan-Kai ; Radzi, Ahmad ; Kang, Jin-Hyoung ; Kim, Sang-We ; Tan, Soo-Yong ; Yang, James Chih-Hsin. / Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer : a combined clinical-molecular pathological approach. In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 ; Vol. 6, No. 10. pp. 1663-9.

@article{f46a124dc2b54b9db921e416d139728a,

title = "Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach",

abstract = "Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols.",

keywords = "Far East, Neoplasm Staging, Receptor, Epidermal Growth Factor, Antineoplastic Agents, Pathology, Molecular, DNA Mutational Analysis, Humans, Drug Resistance, Neoplasm, Asian Continental Ancestry Group, Individualized Medicine, Survival Rate, Lung Neoplasms, Treatment Outcome, Practice Guidelines as Topic, Carcinoma, Non-Small-Cell Lung, Mutation",

author = "Manuel Salto-Tellez and Ming-Sound Tsao and Jin-Yuan Shih and Sumitra Thongprasert and Shun Lu and Gee-Chen Chang and Au, {Joseph Siu-Kie} and Teh-Ying Chou and Jong-Seok Lee and Yuan-Kai Shi and Ahmad Radzi and Jin-Hyoung Kang and Sang-We Kim and Soo-Yong Tan and Yang, {James Chih-Hsin}",

year = "2011",

month = oct,

doi = "10.1097/JTO.0b013e318227816a",

language = "English",

volume = "6",

pages = "1663--9",

journal = "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "10",

}

Salto-Tellez, M, Tsao, M-S, Shih, J-Y, Thongprasert, S, Lu, S, Chang, G-C, Au, JS-K, Chou, T-Y, Lee, J-S, Shi, Y-K, Radzi, A, Kang, J-H, Kim, S-W, Tan, S-Y & Yang, JC-H 2011, 'Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach', Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, vol. 6, no. 10, pp. 1663-9. https://doi.org/10.1097/JTO.0b013e318227816a

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer : a combined clinical-molecular pathological approach. / Salto-Tellez, Manuel; Tsao, Ming-Sound; Shih, Jin-Yuan; Thongprasert, Sumitra; Lu, Shun; Chang, Gee-Chen; Au, Joseph Siu-Kie; Chou, Teh-Ying; Lee, Jong-Seok; Shi, Yuan-Kai; Radzi, Ahmad; Kang, Jin-Hyoung; Kim, Sang-We; Tan, Soo-Yong; Yang, James Chih-Hsin.

In: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Vol. 6, No. 10, 10.2011, p. 1663-9.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer

T2 - a combined clinical-molecular pathological approach

AU - Salto-Tellez, Manuel

AU - Tsao, Ming-Sound

AU - Shih, Jin-Yuan

AU - Thongprasert, Sumitra

AU - Lu, Shun

AU - Chang, Gee-Chen

AU - Au, Joseph Siu-Kie

AU - Chou, Teh-Ying

AU - Lee, Jong-Seok

AU - Shi, Yuan-Kai

AU - Radzi, Ahmad

AU - Kang, Jin-Hyoung

AU - Kim, Sang-We

AU - Tan, Soo-Yong

AU - Yang, James Chih-Hsin

PY - 2011/10

Y1 - 2011/10

N2 - Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols.

AB - Several randomized phase III studies in advanced stage non-small cell lung cancer (NSCLC) confirmed the superior response rate and progression-free survival of using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor as first-line therapy compared with chemotherapy in patients with activating EGFR mutations. Despite the need for EGFR mutation tests to guide first-line therapy in East Asian NSCLC, there are no current standard clinical and testing protocols.

KW - Far East

KW - Neoplasm Staging

KW - Receptor, Epidermal Growth Factor

KW - Antineoplastic Agents

KW - Pathology, Molecular

KW - DNA Mutational Analysis

KW - Humans

KW - Drug Resistance, Neoplasm

KW - Asian Continental Ancestry Group

KW - Individualized Medicine

KW - Survival Rate

KW - Lung Neoplasms

KW - Treatment Outcome

KW - Practice Guidelines as Topic

KW - Carcinoma, Non-Small-Cell Lung

KW - Mutation

U2 - 10.1097/JTO.0b013e318227816a

DO - 10.1097/JTO.0b013e318227816a

M3 - Article

C2 - 21869714

VL - 6

SP - 1663

EP - 1669

JO - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

SN - 1556-0864

IS - 10

ER -

Salto-Tellez M, Tsao M-S, Shih J-Y, Thongprasert S, Lu S, Chang G-C et al. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Oct;6(10):1663-9. https://doi.org/10.1097/JTO.0b013e318227816a